6533b7d1fe1ef96bd125c309
RESEARCH PRODUCT
The extent of HLA-DR expression on HLA-DR+Tregs allows the identification of patients with clinically relevant borderline rejection
Edgar SchmittMartin ZeierStefan MeuerLuis E. BeckerNicole SeisslerSebastian Markus SchaeferRüdiger WaldherrFriederike HugAndrea SteinbornMatthias SchaierClaudia Sommerersubject
AdultGraft RejectionMaleRegulatory T cellRisk AssessmentSensitivity and SpecificityT-Lymphocytes RegulatoryFlow cytometryCohort StudiesPathogenesisYoung AdultPredictive Value of TestsReference ValuesBiopsymedicineHLA-DRHumansSurvival rateAgedSubclinical infectionTransplantationmedicine.diagnostic_testbusiness.industryBiopsy NeedleForkhead Transcription FactorsHLA-DR AntigensMiddle AgedFlow CytometryImmunohistochemistryKidney TransplantationSurvival RateTransplantationTreatment Outcomemedicine.anatomical_structureROC CurveCase-Control StudiesImmunologyLinear ModelsKidney Failure ChronicFemalebusinessBiomarkersdescription
Regulatory T cells (Tregs) were shown to be involved into the pathogenesis of acute rejection after transplantation. The suppressive activity of the total regulatory T cell pool depends on its percentage of highly suppressive HLA-DR(+) -Treg cells. Therefore, both the suppressive activity of the total Treg pool and the extent of HLA-DR expression of HLA-DR(+) -Tregs (MFI HLA-DR) were estimated in non transplanted volunteers, patients with end-stage renal failure (ESRF), healthy renal transplant patients with suspicion on rejection, due to sole histological Bord-R or sole acute renal failure (ARF), and patients with clinically relevant borderline rejection (Bord-R and ARF). Compared to patients with only Bord-R or only ARF, the suppressive activity of the total Treg cell pool was exclusively reduced in patients with clinically relevant Bord-R. In parallel, the HLA-DR MFI of the DR(+) -Treg subset was significantly decreased in these patients, due to a significantly lower proportion of DR(high+) -Tregs, which were shown to have the highest suppressive capacity within the total Treg pool. Our findings clearly demonstrate that the determination of the HLA-DR MFI of the HLA-DR(+) -Treg subset allows a highly sensitive, specific and non-invasive discrimination between patients with clinically relevant Bord-R (Bord and ARF) and patients with subclinical rejection or other causes of transplant failure.
year | journal | country | edition | language |
---|---|---|---|---|
2013-01-02 | Transplant International |